Related Experiment Video

Updated: Jul 4, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Reovirus: viral therapy for cancer 'as nature intended'

C Comins1, L Heinemann, K Harrington

  • 1Department of Oncology, Postgraduate Medical School, University of Surrey, Guildford, UK. c.comins@surrey.ac.uk

Clinical Oncology (Royal College of Radiologists (Great Britain))
|June 28, 2008
PubMed

Insights

Reovirus, a tumor-selective oncolytic virus, shows potential as a novel cancer therapy. Preclinical data and ongoing clinical trials investigating reovirus for cancer treatment are summarized.

Area of Science:

  • Oncology
  • Virology
  • Cancer Therapeutics

Background:

  • Oncolytic viruses selectively infect and lyse tumor cells.
  • Reovirus is a wild-type oncolytic virus being explored for cancer treatment.
  • Understanding reovirus biology is crucial for its therapeutic application.

Purpose of the Study:

  • To provide an overview of reovirus biology.
  • To summarize preclinical data on reovirus's oncolytic capabilities.
  • To review completed and ongoing clinical trials of reovirus in cancer therapy.

Main Methods:

  • Literature review of reovirus biology.
  • Summary of preclinical studies demonstrating oncolytic effects.
  • Analysis of clinical trial data (single agent, combination therapy).

Main Results:

  • Reovirus exhibits tumor-selective infection and lysis.
  • Preclinical data support reovirus's oncolytic potential.
  • Clinical trials are evaluating reovirus efficacy and safety.

Conclusions:

  • Reovirus is a promising oncolytic virus for cancer therapy.
  • Further clinical investigation is warranted to establish its role in oncology.
  • Combination therapies involving reovirus are under active study.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...